B Cell News and Research

RSS

Blast phase characteristics differ in TKI-, non-TKI–treated CML patients

Features of the blast phase, such as blast cell morphology and accompanying cytogenetic changes, vary between chronic myeloid leukaemia patients who received tyrosine kinase inhibitor therapy and those treated in the pre-TKI era, research shows.

12 Jan 2015

Researchers find mechanism that leads to resistance to targeted therapy in melanoma patients

Moffitt Cancer Center researchers have discovered a mechanism that leads to resistance to targeted therapy in melanoma patients and are investigating strategies to counteract it. Targeted biological therapy can reduce toxicity and improve outcomes for many cancer patients, when compared to the adverse effects of standard chemotherapeutic drugs.

12 Jan 2015

INTEGRA expands VIAFLO II electronic pipette range

INTEGRA has expanded its popular VIAFLO II electronic pipette range. Often requested by users of PCR applications, the new 50 µl models perfectly fill the gap between the 0.5-12.5 µl and 5-125 µl ranges. Now available for single-, 8-, 12- and 16-channel VIAFLO II pipettes, the new models deliver optimized precision pipetting in the volume range of 2 – 50 µl.

From INTEGRA Biosciences 12 Jan 2015

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

QIAGEN announced today the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating nucleic acids obtained from blood samples to assess an important genomic mutation in patients with non-small cell lung cancer (NSCLC), the most common form of this cancer.

From QIAGEN Manchester Limited 12 Jan 2015

Virginia Tech scientists plan to design virus to switch wound-healing drug into cancer fighter

At the Virginia Tech Carilion Research Institute, three scientists are planning to create a virus capable of destroying brain cancer.

12 Jan 2015

New insight into molecular mechanism of ancient evolutionary enzyme

A team led by structural biologists at The Scripps Research Institute has taken a big step toward understanding the intricate molecular mechanism of a metabolic enzyme produced in most forms of life on Earth.

12 Jan 2015

ULB researchers uncover new mechanism involved in tumour initiation, growth in SCC

Researchers at the Université libre de Bruxelles (Belgium) report the mechanisms regulating the different functions of Twist1 controlling skin tumour initiation, cancer stem cell function and tumor progression.

12 Jan 2015

Yeast-eating gut bacteria can help battle bowel problems and autoimmune diseases

Human gut bacteria that feast on the yeast contained in fermented foods like bread and beer provides clues to new treatments for people suffering from bowel diseases.

9 Jan 2015

CHLA scientists grow tissue-engineered small intestine from human cells

A new study by researchers at Children's Hospital Los Angeles has shown that tissue-engineered small intestine grown from human cells replicates key aspects of a functioning human intestine. The tissue-engineered small intestine they developed contains important elements of the mucosal lining and support structures, including the ability to absorb sugars, and even tiny or ultra-structural components like cellular connections.

9 Jan 2015

Tips to avoid winter slips and falls

Tread lightly and don't get too confident; winter is officially here and sidewalks are slippery. About 1 million people take a tumble every year and, according to the Centers for Disease Control and Prevention, approximately 20,000 people die annually due to fall-related injuries.

9 Jan 2015

Exposure to nanoparticles can play major role in development of cardiovascular diseases

Nanoparticles, extremely tiny particles measured in billionths of a meter, are increasingly everywhere, and especially in biomedical products. Their toxicity has been researched in general terms, but now a team of Israeli scientists has for the first time found that exposure nanoparticles (NPs) of silicon dioxide (SiO2) can play a major role in the development of cardiovascular diseases when the NP cross tissue and cellular barriers and also find their way into the circulatory system.

8 Jan 2015

Scientists discover potential solution to antibiotic resistance

A newly developed technique for screening microbes has led to the discovery of a powerful new antibiotic that can easily kill severe infections in mice, without causing side effects.

8 Jan 2015

H&P Labs announces licensing agreement to develop oral drug therapy against Ebola

H&P Labs Inc. announced an agreement with Harvard University and Brigham and Women's Hospital to license two classes of compounds in order to develop an oral drug therapy against Ebola.

8 Jan 2015

Enzymes linked to diabetes, obesity play major roles in arthritis and leukemia

Enzymes linked to diabetes and obesity appear to play key roles in arthritis and leukemia, potentially opening up new avenues for treating these diverse diseases, according to new research at Washington University School of Medicine in St. Louis.

8 Jan 2015

New opportunity for developing simple test to measure E2F4 activity in ER+ breast cancer patients

By looking at the expression levels of downstream genes of the regulators in breast cancer, investigators at Dartmouth Hitchcock's Norris Cotton Cancer Center, led by Chao Cheng, PhD, have identified a gene signature in E2F4 that is predictive of estrogen receptor positive (ER+) breast cancer.

8 Jan 2015

Johns Hopkins-led study offers strategy to eradicate HIV

Luring dormant HIV out of hiding and destroying its last cure-defying holdouts has become the holy grail of HIV eradication, but several recent attempts to do so have failed. Now the findings of a Johns Hopkins-led study reveal why that is and offer a strategy that could form a blueprint for a therapeutic vaccine to eradicate lingering virus from the body.

8 Jan 2015

Findings could accelerate development of prebiotic medicines for bowel problems, autoimmune diseases

Bacteria that have evolved to eat their way through yeast in the human gut could inform the development of new treatments for people suffering from bowel diseases.

8 Jan 2015

$ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL$

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi platform, today reported that the first patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has enrolled in the "Wolverine" Phase II study and been treated with PNT2258.

8 Jan 2015

Using HIV drugs to treat AMD: an interview with Dr Mark Young

NRTIs are compounds which were originally developed in the 1960s as anti-cancer agents. They are similar in structure to the bases which make up DNA, and it was hoped that they would interfere with DNA replication in fast-growing cancer cells, slowing down or stopping tumour growth.

7 Jan 2015

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration.

7 Jan 2015

B Cell News and Research

Blast phase characteristics differ in TKI-, non-TKI–treated CML patients

Researchers find mechanism that leads to resistance to targeted therapy in melanoma patients

INTEGRA expands VIAFLO II electronic pipette range

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

Virginia Tech scientists plan to design virus to switch wound-healing drug into cancer fighter

New insight into molecular mechanism of ancient evolutionary enzyme

ULB researchers uncover new mechanism involved in tumour initiation, growth in SCC

Yeast-eating gut bacteria can help battle bowel problems and autoimmune diseases

CHLA scientists grow tissue-engineered small intestine from human cells

Tips to avoid winter slips and falls

Exposure to nanoparticles can play major role in development of cardiovascular diseases

Scientists discover potential solution to antibiotic resistance

H&P Labs announces licensing agreement to develop oral drug therapy against Ebola

Enzymes linked to diabetes, obesity play major roles in arthritis and leukemia

New opportunity for developing simple test to measure E2F4 activity in ER+ breast cancer patients

Johns Hopkins-led study offers strategy to eradicate HIV

Findings could accelerate development of prebiotic medicines for bowel problems, autoimmune diseases

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

Using HIV drugs to treat AMD: an interview with Dr Mark Young

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News